Eiji Tanaka, DVM, PhD, is currently President of Mitsubishi Tanabe Pharma Holdings America, Inc. and Head of Global Business Development for Mitsubishi Tanabe Pharma Group since November, 2014. Dr. Tanaka has more than 18 years of experience as a toxicologist since joining Mitsubishi Chemical Industries, Ltd., one of preceding companies of Mitsubishi Tanabe Pharma Corporation (MTPC), in 1981. Dr. Tanaka attended a postgraduate program in Pharmacology at University of Rochester in New York (1992-1994). After returning to Japan, he held managerial positions such as the Manager of Safety Research Laboratories, Senior Manager of Licensing Department. From 2004 to 2006, Dr. Tanaka was the Senior Manager of Corporate Strategic Planning Department. After serving as General Manager of Business Development and Licensing Department, he became General Manager of International Business Department (IBD) at MTPC in 2011 and he was appointed as Associate Director of IBD in 2013, managing business in China, Korea, Taiwan, Indonesia, ASEAN countries, U.S., and Europe. Since April 2014, Dr. Tanaka has been the Executive Officer of the IBD with further responsibilities.